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Several case reports and studies have alluded to an increased prevalence of 
venous thrombosis in human immunodeficiency virus positive (HIV-positive) 
patients. Although a relationship between HIV infection and thrombotic 
disease has been suggested, the mechanisms predisposing to thrombosis 




A prospective study, to determine possible coagulation factor abnormalities 
that could explain the predisposition to thrombosis in HIV-infected African 




African (Black) patients, with acute upper segment deep vein thrombosis 
(DVT) confirmed by duplex ultrasound, were enrolled. Patients who had 
recognisable risk factors such as recent surgery, pregnancy or malignancy, 
were excluded. After informed consent, blood samples were taken for 
baseline tests as well as a thrombophilia screen. The control group comprised 
known HIV-positive African (Black) patients without DVT. Patients with DVT 
who were found to be HIV-negative were also analysed. 
 
Analysis was done in 2 parts: HIV-positive patients with and without 





Part A: HIV-positive patients with and without thrombosis 
 
Of the 77 patients with DVT, 50 patients tested HIV-positive. These 50 
patients (HIV-positive DVT-arm), as well as 56 controls (HIV-positive, no 
DVT), were enrolled into the study. The groups were well matched with regard 
to age, sex and cluster designation 4 (CD4) count. On univariate analysis, 
significant findings in the DVT-arm were a history of active tuberculosis on 




multivariate analysis, only tuberculosis and an elevated D-dimer proved to be 
significant. 
 
Part B: HIV-positive and negative patients with thrombosis 
 
There were 20 HIV-negative patients with DVT who met our inclusion criteria 
Limited assessment was done on this group owing to unavailability of some 
data. 
 
The mean age of the HIV positive DVT group was significantly lower than the   
HIV-negative group with DVT (31.78 vs. 41.45 years; p=0.005). 
 
There was no significant difference in the prevalence of tuberculosis between 
the HIV-positive and HIV-negative patients with thrombosis (p = 0.269). 
 
Mean protein C levels were reduced in the HIV-positive group and normal in 
the HIV-negative group. They were significantly lower in the HIV-positive 






The findings of the study suggest a relationship between HIV, its 
complications and DVT. Although this study confirms HIV infection as a risk 
factor for thrombosis, clear pathogenetic mechanisms remain to be 
elucidated. In our population, tuberculosis appears to be an important risk 
factor predisposing patients to the development of DVT, both in the HIV- 
positive and negative population. Further studies will need to be done to 
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Thrombosis of veins and arteries, together with complicating embolic 
phenomena, are perhaps the most important causes of sickness and death in 
the developed world at the present time. Venous thromboembolic (VTE) 
disease is the third most common cardiovascular disease after atherosclerotic 
heart disease and stroke.[1] 
 
Deep vein thrombosis principally affects the lower limbs and is highly age 
dependant. It is exceptional in childhood and may reach 1% per year in the 
very elderly.[2] 
 
Venous thromboembolism results from the interaction of multiple risk factors. 
These may be gene-environment interactions or multiple environmental or 
acquired risk factors.[2] Important pathogenetic mechanisms in venous 
thrombosis are stasis and hypercoagulability. 
 
Thrombophilia is the term used to describe disorders of haemostasis, either 
congenital or acquired, which predispose to the development of venous 
thrombosis. The heritable abnormalities include those due to deficiency of the 
natural anticoagulants antithrombin, protein C and protein S, as well as those 
resulting in increased procoagulant activity such as factor V Leiden and 
G20210A prothrombin polymorphism. Acquired conditions that predispose to 






There have been several clinical studies and case reports describing the 
development of deep vein thrombosis in HIV-positive patients in the absence 
of classic thrombophilic risk factors such as advanced age, immobility, family 
history and malignancy. Several intersecting mechanisms associated with HIV 
infection are described that may lead to vasculopathy and hypercoagulability. 
HIV infection may be directly implicated in that it causes endothelial damage 
with the release of cytokines and tissue factor. HIV infection is also associated 
with decreased levels of protein C, S and antithrombin.[3] Many of these 
studies are retrospective small studies and there is still uncertainty regarding 
the incidence and risk factors for thrombosis in HIV-positive patients, including 
the importance of disease stage, associated opportunistic infections and 
antiviral therapy. 
 
KwaZulu-Natal is the epicentre of a devastating HIV epidemic affecting sub-
Saharan Africa. There are no studies describing the prevalence and 
pathophysiology of thrombosis in HIV-positive African (Black) patients in this 
region. Therefore, a study was initiated to examine the prevalence of DVT in 
this population group, as well as to test for possible coagulation factor 
















2. REVIEW OF THE LITERATURE 
Venous thromboembolism (VTE) is a cause of considerable morbidity and 
mortality.[4] The major manifestations of venous thrombosis are deep vein 
thrombosis (DVT) of the lower limbs and pulmonary embolism. Thrombosis 
may also occur in other veins and involve the upper limbs, liver, cerebral 
sinus, retina and the mesenteric veins. Major complications of venous 
thrombosis of the lower limbs are acute death from pulmonary embolism and 
a disabling post-thrombotic syndrome.[5] The fatality rate of venous 
thrombosis, mainly due to pulmonary embolism, ranges from 1% in young 
patients to 10% in older patients.[6] 
 
The annual incidence of venous thrombosis is 1 - 3 per 1000 individuals per 
year.[5] The frequencies of VTE described in the literature strongly depend on 
the patient populations being studied and on the sensitivity and specificity of 
the methods used for diagnosis.[7] Rates of venous thromboembolism increase 
dramatically as the population ages, with 1/10 000 events in the young (< 40 
years old) to 1 per 1000 in the elderly (> 75 years old).[8] 
 
Virchow, in the 19th century, postulated three major causes of thrombosis: 
changes in the vessel wall, changes in blood flow and changes in blood 
composition.[9] This broad classification is still valid today. In venous 
thrombosis, however, the most important factors are stasis and prothrombotic 




be inherited or acquired. Table 1 lists the important causes of venous 
thrombosis.[5] Acquired and genetic causes frequently interact.  
 
Most commonly, thrombosis is the result of more than one “hit”.[11] The 
likelihood of developing thrombosis would depend on the type and the number 
of predisposing factors involved. Acquired risk factors still play a major role in 
the burden of venous thrombosis even though their impact has lessened 
because of the implementation of prophylactic anti-thrombotic strategies.[6] 
The term thrombophilia is used to describe the familial or acquired disorders 
of the haemostatic mechanism which are likely to predispose to thrombosis.[12] 
Patients with inherited thrombophilia generally present with thrombosis at an 













































Antithrombin deficiency High levels of factor VIII 
Pregnancy 
 
Protein C deficiency High levels of factor IX 
Major surgery 
 
Protein S deficiency High levels of factor XI 
Orthopaedic surgery 
 
Factor V Leiden (FVL) High levels of fibrinogen 
Malignancy 
 
Prothrombin 20210A High levels TAFI 
Oral contraceptives 
 




 APC-resistance in the 






















TAFI, thrombin activatable fibrinolysis inhibitor; TFPI, tissue factor pathway 
inhibitor; APC, activated protein C; FVL, factor V Leiden; PCI, protein C 










A familial tendency to venous thrombosis was first described in the early 
1900s when pedigrees with a large number of individuals with venous 
thrombotic events suggested heritable hypercoagulability. Egeberg [13] 
described the first family with an identified hereditary tendency to thrombosis 
caused by antithrombin deficiency in 1965. Subsequently in the 1980s, protein 
C and protein S deficiency were recognised as causes underlying familial 
thrombophilia.[6] Over the last 10 years, several new defects have been 
identified which are commoner, but less thrombogenic when compared to 
deficiencies of protein C, protein S and antithrombin. 
 
The frequency of the major inherited forms of hypercoagulability varies 
substantially within healthy populations and among patients with venous 
thrombosis. Factor V Leiden and the G20210A mutation in the prothrombin 
gene are common among healthy Whites, but extremely rare among Asians 
and Blacks.[10] Since Factor V Leiden and the G20210A mutation are relatively 
common, they can occur together with other thrombophilias. Deficiencies of 
antithrombin, protein C and protein S are found in less than 1% of the 
















Table 2: Prevalence of thrombophilic defects 
 
 






Antithrombin deficiency 1 - 2 
 
0.1 - 0.3 
 
Protein C deficiency 
 
2 - 3 
 
0.2 - 0.5 
 
Protein S deficiency 
 
2 - 3 
 
0.2 - 0.5 
 
Factor V Leiden 
 
10 - 20 
 




10 - 20 
 




5 - 6 
 
1 - 3 
 









Numerous mutations have been described in patients with a deficiency of 
protein C, protein S or antithrombin. Type I defects (low activity and low 
antigen level) predominate in patients with a deficiency of protein C or S, 
whereas both type I and type II (low activity and normal antigen level) defects 
are common in patients with antithrombin deficiency.[10] Deficiencies of protein 
C, protein S and antithrombin increase the risk of thrombosis by about 10-fold 
in heterozygotes. Of these deficiencies, the highest risk is associated with 
antithrombin deficiency.[6] 
 
First identified in 1994, factor V Leiden is the most common genetic 
prothrombotic defect. It is one of the causes of resistance to activated protein 
C (APC). The resistance is due to a defect in the APC cleavage site on factor 




relative risk of thrombosis for carriers is thought to be increased 7-fold for 
heterozygotes and 80-fold for homozygotes.[4] 
 
The prothrombin gene mutation was first discovered in 1996. The defect is a 
G to A nucleoside transition at position 20210 of the prothrombin gene. 
Heterozygote carriers of the gene were found to have approximately 30% 
higher prothrombin levels than healthy controls, and presumably this is the 
mechanism by which it exerts its thrombotic effects.[4] 
 
Mildly elevated levels of homocysteine are associated with an increased risk 
of thrombosis. The mechanism by which hyperhomocysteinaemia affects the 
risk of thrombosis is unknown. Hyperhomocysteinaemia can be caused by 
genetic disorders affecting the trans-sulphuration or remethylation pathways 
of homocysteine metabolism, or by acquired causes such as folic acid 
deficiency, vitamin B12 deficiency, vitamin B6 deficiency, renal failure, 
hypothyroidism, increasing age and smoking.[10] 
 
When investigating for hereditary thrombophilia, it is important to be aware of 
the acquired causes of reduced levels of the factors. Liver disease, oral 
anticoagulants, disseminated intravascular coagulation, vitamin K deficiency 
and nephrotic syndrome are some of the causes of reduced levels of protein 
C, protein S and antithrombin. Also, the timing of the testing is important. In 
the acute phase of deep vein thrombosis, the levels of protein C, S and 
antithrombin could be reduced due to utilisation and, therefore, testing 




the acute phase has resolved. It is most practical to test about two weeks after 
oral anticoagulation has been stopped.[15] 
 
Acquired Thrombophilia 
Acquired conditions that predispose to thrombosis are listed in Table 1. 
Venous stasis is an important pathogenetic factor in venous 
thromboembolism. It contributes to post operative thrombosis and is a factor 
in thrombosis in paralysed limbs as well as limbs splinted in plaster casts. In 
postoperative patients, the procoagulant responses to tissue trauma (such as 
increased fibrinogen and factor VIII concentrations in plasma) and reactive 
thrombocytosis may also play a part. The highest prevalence of VTE occurs in 
major orthopaedic surgery, with the lower limb being the commonest site for  
venous thrombosis.[16] 
 
Indwelling venous devices are a significant cause of deep venous thrombosis. 
Up to 60% of patients with central venous catheters will develop a 
complication, thrombosis being one of the most common.[16] 
 
Cancer is a major risk factor for venous thromboembolism. It is estimated that 
almost 15% of cancer patients will have a thromboembolic event. Cancer 
patients have a high risk of venous thromboembolism after surgery and some 
forms of chemotherapy may also increase that risk. The risk of thrombosis 
varies with the type of cancer, with ovarian, brain and pancreatic cancers 




Iatrogenic venous thromboembolism may be due to pharmaceuticals and 
venous thromboembolism associated with the use of the combined oral 
contraceptive pill is of particular importance because it affects young, healthy 
women. Oestrogen-containing preparations induce a state of reduced 
sensitivity to activated protein C, and this appears to be more marked with the 
third generation contraceptives than second generation preparations. 
Hormone replacement therapy use is also associated with VTE. In this case, 
the absolute risk is higher due to the greater background prevalence of 
venous thrombosis in older women. [16] 
 
Antiphospholipid syndrome is an important thrombophilic condition that is 
associated with considerable morbidity and mortality.  The essential features 
are arterial or venous thrombosis, or recurrent pregnancy loss occurring in a 
subject who has a positive antiphospholipid antibody, and/or a positive lupus 
anticoagulant. Antiphospholipid syndrome may occur in association with 
another chronic systemic auto-immune disease, usually systemic lupus 
erythematosis, when the term secondary antiphospholipid syndrome is 
used.[16] Antiphospholipid antibodies have also been present in association 
with a large number of infectious diseases, such as syphilis, HIV infection, 
malaria and hepatitis C, but are not usually associated with clinical 
complications. [17] 
 
Elevated levels of prothrombin, factor VIII, factor IX, factor XI as well as 
thrombin activatable fibrinolysis inhibitor(TAFI) are all associated with an 




percentile of the distribution in the general population, are associated with a 2 
to 3 fold increase in the risk of thrombosis. Although little is known about the 
origins of such elevated levels, it is likely that they are a combination of 
genetic and acquired causes. Familial clustering of elevated levels of factor 
VIII has been shown.[5]  
 
Thrombosis in Black subjects 
Deep vein thrombosis has been historically perceived as a disorder that 
affects mainly Whites, a belief partly reinforced by the low incidence of 
hereditary prothrombotic mutations in Blacks. Some of the congenital 
thrombophilic disorders such as factor V Leiden and the prothrombin gene 
mutation are extremely rare in Blacks.[14] 
 Understanding of the epidemiology and risk factors for venous 
thromboembolism in Blacks is limited.[34] There are, however, recent studies 
that show that venous thrombosis is equally common amongst a variety of 
racial groups, including Black patients, although the predisposing factors 
appear to differ.[34] . 
 A prospective study [59] was performed during the 2 year period 2000-2001 at 
Kings College, London to ascertain possible ethnic differences in the 
prevalence of DVT. Of the 850 patients who were assessed for suspected 
DVT, 219 patients were found to have DVT. Of the White subjects, 27.7% had 
confirmed DVT relative to 22.8% of the Black subjects. The average age was 
58 years for White persons and 49.3 years for Black persons. Of the 178 
subjects tested, factor V Leiden was found in 21.8 % of White subjects 




significant difference in the incidence of VTE in Blacks and Whites.[59] Patel et 
al. [35,36] found that significant factors in Black patients included elevated D-
dimers as well as elevated factor VIII levels. Their study comprised 125 Black 
patients, 61 with a history of DVT and 64 control subjects. Patients with a 
history of DVT had completed treatment for DVT at least 3 months previously 
and had no intercurrent illness. All subjects were found to have normal 
thrombophilia screens, which included testing for protein C, protein S, 
antithrombin, factor V Leiden and lupus anticoagulant. Median D-dimer was 
significantly higher in cases than controls.[35]  They also  assessed 100 black 
patients with DVT and 100 black controls for elevated factor VIII levels and 
found that 34% of patients with DVT had an elevated factor VIII level 
compared to 10% of controls. In those Black patients with factor VIII below the 
90th centile, the odds ratio for the risk of VTE was 4.64. Conventional 
thombophilia testing was found to be relatively uninformative in Black subjects 
with VTE, revealing a genetic risk factor in only 9.1% of Blacks with VTE as 
opposed to 30% of Whites.  They proposed that raised factor VIII is a major 
risk factor for VTE in Blacks with prevalence and odds ratio exceeding that in 
Whites.[36] Pieper et al. [37] also found significantly higher levels of D-dimer in 
Black persons when assessing a group of community dwelling elderly 
persons. 
 
The Gate (Genetic attributes and thrombosis epidemiology )  study is an 
ongoing case control study in Atlanta designed to examine racial differences 
in venous thomboembolism (VTE) aetiology and pathogenesis. Between 1998 




enrolled. Family history of VTE was reported with equal frequency by cases of 
both races, despite known genetic factors for VTE being rare in African-
Americans. This suggests an as yet unknown genetic component amongst 
blacks and underscores the need for research that specifically addresses risk 
factors and aetiologic mechanisms for VTE in Blacks.[57] 
 
In a Californian study, 17991 patients with idiopathic deep vein thrombosis 
and 5573 patients with secondary thromboembolism were evaluated for ethnic 
origin. The incidence of idiopathic deep vein thrombosis was almost 30% 
higher in African-Americans than in White persons. Similarly, after surgical or 
medical diagnoses, African-Americans had a higher relative risk for 
thromboembolism than White persons.[56]  
 
HIV Infection 
Human immunodeficiency virus infection is a chronic and progressive disease 
that starts as a primary infection and progresses to life-threatening 
opportunistic infections, malignancies and wasting. An effective immune 
system may be maintained for many years in patients with HIV infection, but in 
the majority of cases, the disease progresses and leads to CD4 cell depletion 
and vulnerability to opportunistic infections.[18] 
 
Acquired immunodeficiency syndrome (AIDS) represents the range of 
opportunistic infections, malignancies and wasting manifestations that occur 






By the end of 2005, it was estimated that 38.6 million people world-wide were 
living with HIV infection and about 4.1 million people were newly infected with 
HIV. An estimated 2.8 million lost their lives to AIDS by the end of 2005. The 
prevalence of HIV infection in South Africa is the highest in the world and 
shows no evidence of a decline. The Joint United Nations Programme on 
HIV/AIDS (UNAIDS), reporting on the global HIV/AIDS epidemic, estimated 
that in 2005, 5.5 million (range 4.9 – 6.1 million) people or 18.8% of the 
population were living with HIV/AIDS in South Africa. Almost one in three 
pregnant women attending public antenatal clinics tested HIV-positive in 2004. 
The average life expectancy in South Africa is expected to fall from 60 years 
to 40 years between 1998 and 2008.[19] 
 
Thrombosis in HIV-positive patients 
At the time of the commencement of this study, there were few reports on 
venous thrombosis in HIV-positive patients. These were either case reports or 
small studies attempting to elucidate the problem. 
 
The reported incidence of venous thromboembolism in patients with HIV 
infection ranges from 0.25% to 0.96% in clinical studies, with a 17% incidence 
at autopsy.[20,21] 
 
One of the earliest reports of VTE in HIV-infected individuals was by 
Lafeuillade et al., who reported 2 cases of thrombosis in HIV-positive 




thrombosis of the iliac vein and the inferior vena cava. The second patient 
was a 58-year-old man who presented with ischaemia of the hands and was 
found to have thrombi in the interdigital arteries. On further investigation, both 
patients were found to have free protein S deficiency. To evaluate the 
significance of protein S deficiency, they proceeded to study the prevalence of 
protein S deficiency in 71 HIV-infected patients and found that 22 (31%) had 
low free protein S levels. Using  a functional assay, the mean protein S was  
43%. There was no correlation between low levels and the stage of disease. 
Neither was there any history of thrombosis in any of the patients studied. 
They postulated that protein S deficiency could be due to abnormal 
endothelial cell function secondary to HIV infection and that further studies 
would be required to evaluate the pathophysiology as well as the clinical 
significance of the deficiency of protein S. 
 
Bissuel et al. conducted a prospective analysis of 63 HIV-infected patients at 
various stages of the disease and compared them to a matched control group 
of 24 HIV-negative healthy subjects.[23] The mean age of the patients was 
34.1 years. Forty-one (41) of the 63 patients had low free protein S levels. A 
significant decrease in free protein S levels was found in HIV-positive patients, 
compared to the control group (p = 0.0001). Free protein S levels were 
significantly lower in patients with acquired immuno-deficiency syndrome 
(AIDS) when compared to the group who did not have AIDS (p = 0.0001). 
In addition, total protein S levels were lower in HIV-positive patients compared 
to controls. On evaluation of total protein S levels in the HIV-positive group, no 




was found. There was a significant correlation between total and free protein 
S values (p = 0.0006) but free protein S levels remained lower than total 
protein S. Only 3 HIV-positive patients had protein C deficiency and one of the 
39 patients tested had antithrombin deficiency. Despite the significant 
deficiency in free protein S, only three patients presented with a thrombotic 
event. All three patients had full blown AIDS and were deficient in protein S. 
One of the patients had cytomegalovirus infection, which could have 
predisposed to thrombosis, and the other two had other active infections. The 
details of the infections were not specified. 
 
Stahl et al.[24]  examined the possible predisposing factors to thrombosis in 25 
randomly selected HIV-positive patients with a mean age of 38.6 years. 
Their mean CD4 count was 226/mm3. Three of the 25 patients gave a history 
of thrombosis, occurring after HIV seroconversion. Coagulation studies 
showed that all three of the patients with thrombosis and 16 of the 22 patients 
without thrombosis had decreased free protein S levels. Mean free and total 
protein S levels were lower compared to healthy controls. Decreases in 
protein S levels did not correlate with CD4 levels.  Inflammation may  result in  
an increase in C4b-binding protein, which can shift the protein S from the free 
to the bound form. In patients with decreased free protein S levels, C4b-
binding protein was not increased, thus excluding inflammation as a cause for 
the decreased levels of free protein S. Of note all 25 patients had normal 
protein C, antithrombin and plasminogen levels. In addition, none of the 
patients were positive for a lupus inhibitor as measured by the tissue 




patients and IgG antibodies were positive in 18 of 24 patients. The authors 
concluded that the pathogenesis of decreased protein S remained unclear 
and postulated that disturbances in endothelial function may play a role in the 
aetiology of protein S deficiency. They also suggested that protein S 
deficiency might be a predisposing factor in the development of thrombosis. 
 
Hassel et al.[25]  evaluated the occurrence of antiphospholipid antibodies and 
free protein S deficiency in HIV-infected men and sought to determine the 
possible role of these abnormalities in the development of thrombosis. They 
studied 74 HIV-infected men at all stages of infection. Antiphospholipid 
antibodies were detected in 63 (86%) of the patients tested. Sixty-five per cent 
(65%) had elevated IgG anticardiolipin (aCL) antibodies and 32% had 
elevated IgA aCL antibodies. Only 14% of patients tested had elevated IgM 
aCL antibodies (10 of 67 patients) and a positive dilute Russell viper venom 
test (6 of 43 patients). Low total protein S was detected in eight patients 
(11%), five of whom had low levels of free protein S. Overall there was a 
significant linear correlation between total and free protein S levels (p = 
0.004), but isolated deficiency of free protein S was detected in 23 additional 
patients. C4b-binding protein was measured and was not found to be a 
contributing factor for the decreased free protein S. There was no correlation 
between free protein S (PSF) levels and anticardiolipin antibody titres. There 
was also no correlation between these parameters and CD4 count, 
medication use or infections. The overall incidence of thrombosis in this group 
was 18%. Development of thrombosis was not significantly correlated with 




further studies were required to elucidate the  thrombotic risk in HIV-positive 
patients. 
 
The presence of  lupus anticoagulants and anticardiolipin antibodies has been 
reported in association with AIDS. The prevalence of lupus anticoagulant  in 
HIV-positive patients has been reported to be as high as 53 - 70% in some 
series and has been noted to be absent in others. Lupus anticoagulant has 
been  associated with thrombosis in certain disease states, such as systemic 
lupus erythematosis, but the association with thrombosis in HIV infection 
appears to be rare. Anticardiolipin antibodies have been reported in 46% to as 
many as 90% of patients with HIV infection, but have been rarely associated 
with thrombotic events.[26] 
 
Sorice et al. evaluated protein S levels in patients with HIV infection, none of 
whom had thrombosis.[27] They tested 35 patients with HIV infection and found 
23 (65.7%) had reduced free protein S activity and 20 (65.7%) had reduced 
free protein S antigen. They found that free protein S levels, tested either by 
activity or antigenic method, were reduced in HIV-positive patients when 
compared to controls. They also found that protein S levels were significantly 
lower in patients with CD4 counts less than 100 cells/mm3. In an attempt to 
ascertain the cause of the reduced protein S levels, they tested for anti-protein 
S antibodies and found that 28% of patients had anti-protein S antibodies. 
There was a higher prevalence of antibody positivity in symptomatic patients 




suggested that one of the causes of reduced protein S levels was the 
presence of specific antibodies. 
 
In view of the uncertainty regarding the causes of thrombosis in HIV-infected 
patients, Feffer et al. analysed 52 HIV-positive individuals and screened them 
for possible predisposing factors for the development of thrombosis.[28] None 
of the patients had thrombosis. Patients were grouped into 3 categories based 
on their CD4 counts. They found decreased levels of protein C and free 
protein S, along with elevated levels of total protein S and von Willebrand 
factor. The increased total protein S and von Willebrand factor were thought to 
be due to endothelial injury resulting from HIV infection. These results 
correlated with the degree of immunosuppression as measured by CD4 
counts. The relation of free protein S levels and the patients’ CD4 levels 
concurs with the results of Bissuel et al.[23] and differs from those reported by 
Stahl et al.[24] and Lafeuillade et al.[22] Also, contrary to the findings by Stahl et 
al. and Lafeuillade et al., they found an inverse relationship between free 
protein S and C4b-Binding-Protein (C4b-BP). They also detected a significant 
elevation of D-dimers in patients with inflammatory/neoplastic disease and 
proposed that a low grade consumptive coagulopathy was responsible for the 
decline in protein C levels. They postulated that the predisposition to 
thrombosis was as a result of a combination of consumptive coagulopathy, 
endothelial damage and a decline in free protein S. 
 
In a review by Laing et al., the authors alluded to the difficulty in establishing 




asymptomatic thrombi may not be diagnosed and fatal pulmonary emboli 
missed unless a post-mortem was performed.[14] The other area of difficulty 
was to elucidate the possible causative factors in these patients. Many of 
these patients were chronically ill and debilitated and probably had multiple 
predisposing factors for the development of thrombosis. 
 
A longitudinal review of over 100 medical clinics was done by Sullivan et al. in 
which they assessed 42 935 patients with HIV infection.[29]  A total of 335 
instances of thromboses were documented in 273 patients. Forty three (43) 
patients had more than one thrombotic event. The incidence of thrombosis 
was 2.6/1000 person years in this group. The incidence was higher in patients 
with clinical AIDS as compared with immunological AIDS. Factors significantly 
associated with thrombosis were age ≥ 45 years, diagnosis of 
cytomegalovirus infection or other AIDS-defining opportunistic infections, 
hospitalisation and the prescription of megesterol acetate or indinavir. They 
were unable to evaluate the relative importance of the predisposing factors for 
thrombosis as they did not have information on variables such as protein S 
and anticardiolipin antibodies. 
 
Saif et al. evaluated 131 HIV-positive patients retrospectively.[30] Ten (10) 
patients experienced 15 episodes of unexplained deep vein thrombosis. All 
were male with a mean age of 39.3 years. Six patients had lower extremity 
deep vein thrombosis, 3 developed pulmonary embolism and the others had 
subclavian or axillary vein thrombosis. A history of catheter placement was 




patients had a malignancy: one had non-Hodgkin’s lymphoma and the other 
had Kaposi’s sarcoma. Three patients were bedridden at the time of the 
thrombotic disease. Only 5 out of the 10 patients were evaluated for a 
hypercoagulable state. Abnormal findings were found in 3 of these patients. 
One had anti-thrombin deficiency attributable to HIV-associated nephropathy, 
another had protein C deficiency and the third had positive anti-phospholipid 
antibodies. Thirteen (13) of the 131 patients were on protease inhibitors and 
only 2 patients in this group developed thromboembolism. A significant 
correlation between thrombotic events and CD4 counts was found. Nine (9) of 
10 patients with thrombosis had a CD4 count of < 200 cell/mm3. The authors 
concluded that AIDS appeared to predispose to thrombosis but that further 
studies were required to elucidate the mechanism involved in HIV-related 
thrombosis. Factors postulated as having a role in the predilection for 
thrombosis included abnormalities in the haemostatic pathway, AIDS-related 
opportunistic infections and malignancies. 
 
Saber et al. conducted a retrospective review of HIV-infected patients with 
DVT from January 1995 to January 2000.[31] Of 4 752 HIV-positive patients 
admitted, 45 (0.95%) were found to have DVT. Thirty-six (36) patients were 
males and 9 were female, with a mean age of 43 years. Of the 45 patients, 38 
had infectious complications, with the most common infection being 
cytomegalovirus. Other infections encountered were pneumocystis carinii, 
toxoplasmosis, candidiasis, hepatitis B or C and mycobacterium avium. 
Thirteen (13) patients developed a malignancy, the most common being 




ambulatory at the time of diagnosis. Four patients gave a history of recent 
surgery (within one month of diagnosis of DVT). Data on hypercoagulability 
was obtained in 11 patients only. Protein S deficiency was found in 3 patients, 
anti-thrombin deficiency in 2, and 2 patients had anti-cardiolipin antibodies. 
Thrombosis occurred in the popliteal vein in 20 patients (44.4%), femoral vein 
in 23 patients (51.1%) and ileo-femoral in 2 patients (4.5%). Twelve of the 45 
patients had more than one episode of DVT. According to Rosendaal, one in 
1000 adults in the general population suffers from DVT.[32] In Saber’s study, 
he found that almost one in 100 patients had DVT in the HIV-infected 
group.[31] He attributed the higher risk of DVT in this group to the wide range 
of comorbidity associated with HIV. He is also of the opinion that 
hypercoagulability, opportunistic infections and malignancies make patients 
with HIV more prone to developing thrombosis and that the interactive 
synergistic effect of these risk factors may explain the exaggerated thrombotic 
phenomenon in these patients. 
 
Copur et al.[20] in a retrospective study (between July 1998 and June 1999) of 
patients with venous thromboembolism and/or HIV infection, reported a 
frequency of VTE in patients with HIV infection, regardless of age, of 2.8% 
compared to 1.8% in the non-HIV infected patients. The difference was not 
statistically significant (p = 0.16). However, when the study population was 
divided into those less than 50 years and those greater than 50 years, a 
significant interaction between HIV infection and VTE was found. In those 
patients < 50 years, the frequency of VTE was 3.31% in the HIV-positive 




rate of VTE in the older group of HIV- negative patients (3.04%) was greater 
than in the younger HIV-negative patients (0.53%) (p < 0.0001). Risk factors 
for VTE (pregnancy, malignancy, obesity, surgery, and immobilisation) were 
present in 30% of HIV-positive patients < 50 years of age, in contrast to 60% 
of HIV-negative patients < 50 years of age. They concluded that VTE is a 
potential cause of increased morbidity in HIV-positive individuals less than 50 
years and that HIV should be considered as a possible risk factor in young 
patients with idiopathic VTE. However, the reason for the association 
remained unclear. 
 
Many of the above studies have alluded to the increased prevalence of 
venous thromboembolism in HIV-positive patients. The incidence was 
increased two- to ten-fold in comparison with a healthy population of the same 
age. A variety of predisposing mechanisms have been postulated. However, 
these studies were mainly retrospective cohort studies that were prone to 
selection bias, confounding factors were not always mentioned, diagnostic 
work-up was not always clear and data was sometimes incomplete.[33] Figure 
1 summarises the postulated predisposing factors for the development  of 




















































































A prospective study, to determine possible coagulation factor abnormalities 
that could explain the predisposition to thrombosis in HIV-infected African 
(Black) patients. 
 
Evaluation and comparison of levels of coagulation factors in: 
 
• HIV positive patients with and without DVT 
 
 







African (Black) patients over 18 years of age with acute upper segment deep 
vein thrombosis were considered for entry into the study. Patients with DVT 
were recruited from the diagnostic vascular laboratory, wards and clinics at 
King Edward VIII Hospital. 
The control group was made up of patients who were known to be HIV-
positive but without any symptoms or signs suggestive of thrombotic disease. 
These patients were recruited from the HIV clinic and the wards at King 







 past history of thrombophilia 
 obvious cause of thrombosis, e.g., malignancy 
 diabetes mellitus 
 post-operative states 
 chronic deep vein thrombosis 
 any patient  already commenced on anticoagulants 
 patients who refused HIV testing 
. 
 
PLAN OF INVESTIGATION 
 
STUDY DESIGN 
Patients were analysed in two groups: 
Group A 
A case controlled study group comprising HIV-positive patients with and 
without thrombosis. 
Group B 
An analytical cross sectional group comprising HIV-positive and HIV-negative 










.DESIGN AND EXPERIMENTAL PROCEDURES 
 
Patients with suspected DVT were subjected to duplex ultrasound at the 
vascular laboratory at King Edward VIII Hospital. 
 
Upper segment deep vein thrombosis of the lower limbs is defined as venous 
thrombosis of the iliac, femoral and or popliteal veins, i.e., thrombosis above 
the popliteal trifurcation. 
 
Any patient positive for acute upper segment DVT, who did not have any 
obvious risk factors as outlined in the exclusion criteria, was enrolled in the 
study. 
 
Known HIV-positive patients without symptoms of DVT were enrolled into the 
control arm. Duplex Ultrasound was not performed in this group. 
 
Informed consent for enrolment in the study was obtained from all patients. 















• relevant past medical history 
• relevant family history 
• relevant past or family history of coagulation disorders 
• drug history 
• current medical illness/symptoms 
• duration of presenting symptoms 
• HIV status (if previously tested) 
• site of thrombosis 











After obtaining informed consent, patients were counselled prior to HIV 
testing. (Patients who tested HIV-positive and who wished to be informed of 
the result, received post-test counselling). 
 
Venous blood was drawn for the following tests: 
(1) Full blood count (FBC) 
• 3ml of blood collected in a tube containing ethylenediamine tetra-
acetic acid (EDTA) 
• FBC was assayed via standard Beckman coulter routine (STKS) 
 
(2) Urea and electrolytes (U&E) and liver function tests (LFT) 
• 3ml of blood collected in a plain tube 
• U&E and LFT were processed via Beckman Syncoun CX7 
 
(3) HIV assay 
• 3ml of blood collected in a plain tube 
 
(4) Antinuclear factor (ANF) and anti-cardiolipin antibodies (ACA) 
• 3ml of blood collected in a plain tube 
• ANF and ACA were processed by the immunology laboratory using 





(5) Protein C, total protein S, anti-thrombin (AT) , activated protein C 
resistance, prothrombin index/partial thromboplastin time (PI/PTT), 
qualitative D-dimer and lupus anticoagulant.  
• 2 X 5ml of blood collected in tubes containing 3.2% sodium citrate 
• PI/PTT/Fibrinogen:  analysed using ACL 300 (Ilex  S.A.) 
• Fibrinogen was measured with the derived method 
• Qualitative D-dimer screen was performed  using a latex agglutination 
test for qualitative determination of fibrin D-dimer. We utilised the 
Minutex D-dimer kit.[55] 
• Citrated blood was obtained for protein C, protein S, APC resistance, 
AT and lupus anticoagulant. Samples were spun, aliquoted and stored 
at -700 C 
o Anti-thrombin: done with a kit: chromogenic method 
o Protein C: kit method: SA Scientific: chromogenic method 
o Functional Total Protein S: kit method: ILEX clottable 
technique 
o Lupus anticoagulant: Reagent: Russel viper venom 
o APC Resistance kit method: SA Scientific 
 












• 3ml of blood collected in an EDTA tube 
• CD4: specimens were subjected to monoclonal antibodies after 
being aliquoted in 100ul portiSample incubated for 30 minutes, then 
passed through the Coulter workstation. Red cells were lysed and 
white cells stabilised. Samples were passed through the Coulter 
Epics II Profile flow cytometer. 
 
All specimens were subjected to routine quality control in the laboratory. 
 
ETHICAL ISSUES 
The study protocol was submitted and approved by the research ethics 
committee prior to commencement of the study. Informed consent was 
obtained from all participants in the study. 
 
STATISTICAL ANALYSIS 
Ms Eleanor Gouws (statistician) was consulted regarding sample size and 
design. 
 
Assistance with data analysis was obtained from Ms Tonya Esterhuizen 
(biostatistician) on completion of the study. The statistical analysis was 
performed using the SPSS statistical package. Categorical variables were 







Analysis of Risk Factors 
 
The risk factors were categorised as follows: 
 
 
Risk Factor Category 1 Category 2 
Tuberculosis No Tuberculosis / 
?Tuberculosis 
Tuberculosis 
on  treatment 
 
Platelets normal/low:<450x 109/l high: ≥ 450 X 109/l 
 
Fibrinogen normal / low: < 4.5g/l 
 
elevated: ≥ 4.5g/l 
D-dimer negative D-dimer < 500 positive D-dimer  ≥ 500 
 
ANF negative positive 
 
ACA negative positive 
 
Lupus anticoagulant negative : < 45 seconds 
 
positive: ≥ 45 seconds 
Protein C levels: 
 
elevated or normal: ≥ 70 % low: < 70% 
 
 
Total protein S: 
 





elevated / normal: ≥ 80% low: < 80% 
 
Globulins low/normal: ≤ 32g/l 
 
elevated:     > 32g/l 
CD 4 counts 
 
CD4 ≥ 200cells/mm3 CD4  < 200 cell s/mm3 
 









Analysis was done as follows: 
Group A 
To identify possible risk factors, the baseline characteristics of HIV-positive 
patients who had deep vein thrombosis were compared with the baseline 
characteristics of HIV positive patients without deep vein thrombosis. The risk 
factors were tested for association of HIV and DVT using log rank tests. 
 
Group B 
Eligible patients with DVT who were found to be HIV-negative were compared 
to the HIV-positive group with thrombosis. Odds ratio (OR) with 95% 
confidence intervals (CI) were calculated separately for each parameter by 
means of backward elimination based on likelihood ratio tests. All tests were 
two-sided and p ≤ 0.05 was considered statistically significant. 
 
Tuberculosis was included in all models. Variables with a p value of ≤ 0.05 on 
univariate analysis were entered into multivariate logistic models. When an 
association was identified, a composite model was built with baseline 
covariates to evaluate the effect of adjusting for other important covariates. 
 
The baseline covariates analysed were: 
(1) Sex 
(2) Tuberculosis 






A total of a hundred and thirty three (133) African (Black) patients were 
enrolled from November 1997 to May 2002 at the King Edward VIII hospital in 
Durban. Recruitment of patients was via the vascular laboratory, outpatient 
clinics or by referral of inpatients by doctors who were managing these 
patients. None of the patients had a history of previous deep vein thrombosis, 
a family history of thrombosis, malignancy or recent surgery. None of the 
female patients were on oral contraceptive agents. All subjects were 
antiretroviral therapy naïve. 
 
Of the 133 patients, seventy seven (77) were found to have acute upper 
segment deep vein thrombosis of the lower limb. Fifty five (55) of the 77 
patients with DVT were HIV-positive. Fifty six (56) HIV-positive patients 
without thrombosis formed the control arm. Five patients from the HIV-positive 
DVT arm were excluded from the study because of inconclusive data. 
Eventually 128 patients were analysed. 
 
As outlined earlier, analysis was done in 2 parts: 
 
Group A: HIV-positive patients with and without DVT 
 
Group B: HIV-positive and negative patients with DVT 
 
 





ENROLLMENT AND BASELINE CHARACTERISTICS (Table 3) 
Demographic characteristics 
Fifty HIV-positive patients with deep vein thrombosis (who formed the HIV- 
positive DVT-arm) were enrolled on to the study. 
 
The control arm consisted of 56 patients who were HIV-positive without a 
history of DVT. 
 
In the HIV-positive DVT-arm, 19 patients had right-sided DVT, 25 had left-
sided DVT and 6 patients had bilateral DVT. 
 
There were more females in the control-arm than in the DVT-arm (40 vs. 30), 
but this was not statistically significant (p = 0.215). 
 
The mean age of the patients was 32 years in both arms. Forty-two (42) of the 
50 patients in the HIV Pos DVT arm were less than 40 years of age and 22 of 














CD4 counts were available in 30 of the 50 patients in the HIV-positive DVT- 
arm and in 50 of the 56 patients in the control-arm.  The mean CD4 count was 
lower   in the HIV-positive DVT-arm (202.70 vs. 233.74 cell/ mm3). The 
difference was not statistically significant (p = 0.461). Of the patients tested, 
17 (56.7%) in the HIV-positive DVT-arm and 26 (52%) in the control-arm had 
CD4 counts < 200 cells/mm3. 
 
Comorbidities 
Twenty-two (22) of the patients in the HIV-positive DVT-arm and 11 patients in 
the control-arm were on treatment for tuberculosis (TB) at presentation. This 
information was obtained from the patients. Details of duration, type of TB 
treatment and site of TB were not obtained. No details on the exact drug 
regimen were obtained. The difference between the HIV-arm and the control- 
arm was statistically significant (p = 0.015).  
 
As per the exclusion criteria, none of the patients enrolled had a history of 























































No. of patients analysed 
 
< 200 cells/mm3 
 
≥ 200 cells/mm3 
 

















































































































HAEMATOLOGICAL AND BIOCHEMICAL PARAMETERS 
 
Table 4: Comparison of mean values for haematological and biochemical 



































































































* Statistically significant at 0.05 level 










The mean haemoglobin was significantly lower in the HIV-positive DVT-arm (p 
= 0.024). 
The   mean platelet count was higher in the HIV-positive DVT-arm, but was 
within the normal range and the difference was of borderline statistical 
significance (p = 0.058). In the HIV-positive DVT-arm, only one patient had an 
elevated platelet count (>450 X 109 /L). 
The mean white cell count was higher in the HIV-positive DVT-arm (7.11 vs. 
5.82), but within the normal range. The difference was statistically significant 
(p = 0.020). 
The mean urea and creatinine values in both arms were within the normal 
range. 
The mean globulin level was increased in the HIV-positive DVT-arm 
compared to controls, but this was not statistically significant (p = 0.20). In the 
HIV-positive DVT-arm, 17 of 37 patients (46%) analysed had elevated globulin 
levels, compared to 16 of 50 patients (32%) in the control arm. 
Mean albumin levels were lower in the HIV-positive DVT-arm and this was 
statistically significant (p < 0.001). 
Only 3 out of the 82 HIV-positive patients analysed had a positive anti-nuclear 
factor (ANF). Two (2) of these patients were in the HIV-positive DVT-arm. 
The anticardiolipin antibody (ACA) was positive in 18 of the 46 patients (39%) 
tested in the HIV-positive DVT-arm and 26 of the 47 patients (42%) tested in 
the control arm. The difference was not statistically significant (p = 0.834). 




The mean international normalised ratio (INR) and partial thromboplastin time 
(PTT) were within the normal range in both the HIV-positive DVT-arm and 
control-arm and there was no statistical difference between the two arms. The 
mean fibrinogen was slightly lower in the HIV-positive DVT-arm (4.08 vs. 
4.24). 
The mean total protein S level was lower in the control arm compared to the 
HIV-positive DVT-arm (69.29% and 81.15% respectively) and the difference 
was statistically significant (p = 0.047). However, both levels were within the 
normal range (60 - 140 %). 
The mean protein C level (66.9%) was reduced in the HIV-positive DVT-arm 
and normal in the control-arm (80.38%). The difference between the two 
groups was statistically significant (p = 0.016). Twenty six (26) of 43 patients 
(60.1%) analysed in the HIV-positive DVT-arm had low protein C levels as 
compared to 19 of 50 patients (38%) in the control-arm. 
The mean antithrombin levels were normal in both the control and HIV-
positive DVT-arms and there was no statistically significant difference 
between the two arms (p = 0.661). 
Of the 41 patients analysed in the HIV-positive DVT-arm, 4 had an elevated 
lupus anticoagulant. Seven (7) of the 50 patients tested in the control-arm had 
an elevated level. 
The mean activated protein C resistance values were normal in both groups. 
Of the 26 patients analysed in the HIV-positive DVT-arm, all had normal 
activated protein C resistance levels. 
 




INR, international normalised ratio; PTT, partial prothrombin time;  
APCR, activated protein C resistance 








































































































In the HIV-positive DVT-arm, 23 of 31 patients (74%) analysed had positive D-
dimer screens (> 500ng/ml). Twelve of the 40 control patients (24%) had 
positive D-dimer screens.   The difference between the HIV-positive DVT-arm 
and the control-arm was statistically significant (p < 0.001). Table 6 depicts 








D-dimer Level HIV-positive  
DVT 
HIV-positive 


































BIVARIATE AND MULTIVARIATE ANALYSIS OF DATA (Tables 7 and 8) 
















































High: ≥ 450 








































































< 200 cells/mm3 












































































































































































* Statistically significant at 0.05 level 
 










Table 8: Comparison of HIV-positive patients with DVT and without DVT 
























* Statistically significant at 0.05 level 
OR = odds ratio; CI = confidence interval 
 
Both arms were well matched with regard to age and sex. 
 
The factors that were significant on bivariate analysis were active tuberculosis 
on treatment, low protein C levels and a positive D-dimer screen (Table7). 
 
On multivariate analysis, only tuberculosis and D-dimer positivity were found 













Group B: HIV-positive and negative patients with DVT 
 
 
BASELINE CHARACTERISTICS: GROUP B (Table 9) 
 
 
Patients with upper segment DVT who did not have any identifiable risk 
factors as mentioned in our exclusion criteria were recruited into the study. 
When tested for HIV status, the majority of these patients were HIV-positive, 
i.e., 50 patients. Only 22 patients were HIV-negative. The HIV-negative 
patients with thrombosis were compared to the HIV-positive cohort with 
thrombosis. 
The mean age of the HIV-negative DVT group was significantly higher than 
the   HIV-positive group with DVT (p=0.005). There were relatively more 
males in the HIV-negative arm compared to the HIV-positive arm, but the 
difference was not statistically significant. 
There was no significant difference between the 2 arms with regard to site of 
DVT. However, a higher percentage of patients in the HIV-negative arm had 
bilateral thrombosis (31% vs. 12%). Four of the 13 patients with bilateral DVT 
(2 in the HIV-positive group and 2 in the HIV-negative group) had a history of 
tuberculosis on treatment and a further 3 patients were being investigated for 
possible tuberculosis.  
Seven of the 22 patients in the HIV-negative group gave a history of being on 
treatment for tuberculosis. There was no significant difference in the 
prevalence of tuberculosis between the HIV-positive and HIV-negative 









Table 9: Baseline characteristics of HIV-positive and HIV-negative 






























































































The mean platelet count was higher in the HIV-negative patients with 
thrombosis compared to the HIV-positive group with thrombosis and this was 
of borderline significance (p =0.06). 
 
Mean fibrinogen levels were significantly higher in the HIV-negative group 
(p = 0.05). 
 
Mean protein C levels were reduced in the HIV-positive group and were 
significantly lower in the HIV-positive patients compared to the negative cohort 
(p=0.02). 
 
Mean protein S levels were normal in both groups, but significantly lower in 
the HIV-positive group (p =0.04). 
 
Mean antithrombin levels were normal in both groups and there was no 
significant difference between them (p=0.72). 
 
Mean albumin levels were significantly reduced in the HIV-positive patients 
with thrombosis compared to the HIV-negative group (p=0.02). 





Table 10: Mean values haematological and biochemical parameters in 







































































































BIVARIATE ANALYSIS OF RISK FACTORS: GROUP B (Table 11) 
 
 
On bivariate analysis, significantly more patients in the HIV-positive group 
with thrombosis had reduced protein C levels compared to the HIV- 
negative cohort with thrombosis (p =0.011). 
 
Also, significantly more patients in the HIV-positive DVT group had 
reduced protein S levels compared to the HIV-negative group. Of note, 
none of the patients in the HIV-negative group had reduced protein S 
levels. 
 
Both the HIV-positive group and the HIV-negative group had reduced 
antithrombin levels in 15% of the patients tested (2 of 13 in the HIV-
negative group and 6 of 41 in the HIV-positive group). 
 
Only one of the 16 patients tested in the HIV-negative group had elevated 
globulin levels compared to 17 of the 37 patients in the HIV-positive 



















Table 11: Bivariate analysis of risk factors in HIV-positive and negative 





































































































































































Venous thrombotic disease can be a serious and potentially fatal complication 
of HIV infection. Clear insight is needed into the risk of venous thrombotic 
disorders in HIV-infected patients in order to plan the optimal interventions to 
prevent DV. This entails an understanding of the relationship between HIV 
and DVT, the mechanisms responsible for DVT in HIV-infected individuals and 
the risk factors for DVT in HIV-infected individuals. 
There are uncertainties regarding the incidence of and the risk factors for 
thrombosis in HIV-infected patients.[3] A number of studies have suggested 
that the risk of deep vein thrombosis was higher in HIV-infected individuals. 
Klein et al. [33] performed a systematic review of the literature and identified 
ten relevant epidemiological studies that investigated the risk of venous 
thrombosis in HIV-infected patients. The incidence was increased 2- to 10- 
fold in comparison to a healthy population of the same age. However, these 
studies were mainly retrospective cohort studies that were prone to selection 
bias. Confounding factors were not always mentioned and in many studies, 
control populations were missing. They concluded that an increased risk of 
venous thrombotic events could be explained by the presence of a  
hypercoagulable state characterised by an increase in procoagulant factors 
such as endothelial tissue factor expression and thrombogenic properties of 
microparticles, and a decrease in anticoagulant factors (including antithrombin 




Furthermore, the risk of venous thromboembolism was associated with an 
increased risk of infection and was weakly associated with highly active anti-
retroviral therapy (HAART). The evidence pointed towards a relationship 
between HIV infection and venous thrombotic disease, but they concluded 
that this association needed to be established in well-designed 
epidemiological studies.[33] 
 
This study of  African (Black) HIV-infected patients attempted to ascertain 
possible coagulation system abnormalities as risk factors for deep vein 
thrombosis in  Black HIV-positive patients. All the patients were antiretroviral 
therapy naïve. None of the patients had recognised risk factors for thrombosis 
such as malignancy or previous surgery. 
 
Altogether 126 patients were enrolled onto the study. There were 72 patients 
in the DVT-arm and 56 patients in the control-arm (HIV-positive patients 
without thrombosis). In the DVT-arm there were 50 patients who were HIV- 
positive whilst 22 patients were HIV-negative. Six (6) of the patients in the 
HIV-positive DVT-arm and seven patients in the HIV-negative thrombosis 
group had bilateral thromboses. 
 
Comparative analysis was done in two parts. In group A HIV-positive patients 
with and without thrombosis were analysed, whilst in group B HIV-positive and 
negative patients with thrombosis were analysed. In group A there were more 
females compared to males both in the HIV-positive DVT-arm (30 of 50) as 





the subjects with proven thrombosis (Group B), there were more males in the 
HIV-negative thrombosis arm compared to the HIV-positive thrombosis arm 
and this was of borderline significance (p =0.064). 
 
All the patients and control subjects in the cohort were African (Black) patients 
who developed thrombosis in the absence of the classic well-recognised risk 
factors such as surgery and malignancy. Understanding of the epidemiology 
and risk factors for venous thromboembolism in the Black population is 
limited.[34] Venous thrombosis has historically been perceived as a disease 
restricted to White populations, a belief reinforced by the low incidence of 
known hereditary prothrombotic mutations in Blacks together with the lack of 
diagnostic services in underdeveloped countries. Furthermore, data on 
thrombosis in Africa is limited [60] and our findings are an important 
contribution to research on thrombosis in Blacks in Africa. 
Recent reports suggest that venous thromboembolism is common across a 
variety of racial groups including Africans.[34]  In a prospective study performed 
to ascertain possible ethnic differences in the prevalence of DVT, no 
significant difference was found  in Black subjects compared to Whites.[59]   
White et al. [56]  reported an almost 30% higher incidence of idiopathic venous 
thrombosis in African-Americans compared to Whites. 
 
The mechanisms for predisposition to thrombosis in Blacks, however, may 
differ. Some of the congenital thrombophilic disorders such as factor V Leiden 




 Patel et al. [35,36] found that significant factors in Black patients included 
elevated D-dimers as well as elevated factor VIII levels.  Pieper et al. [ 37]  also 
found significantly higher levels of D-dimer in Black persons when assessing a 
group of community dwelling elderly persons. Significantly elevated qualitative 
D-dimer levels were found in our HIV-positive patients with thrombosis (74% 
of HIV-positive patients with thrombosis had an elevated D-dimer compared to 
24% of HIV-positive patients without thrombosis). The significance of this as a 
predisposing factor is unclear as D-dimer levels can also be elevated in acute 
thrombosis.[6] D-dimer results were not available for the HIV-negative cohort 
with thrombosis and analysis was not possible. Further studies would need to 
be done in our population to establish baseline levels and to repeat the test in 
patients with DVT after the acute event has subsided.[35] 
 
The mean age of the HIV-positive patients in this study was 32 years (32.43 in 
the DVT-arm and 32.86 in the control-arm). Only 5 patients in the HIV- 
positive DVT-arm were over 50 years of age. Twenty-two (22) patients in the 
HIV-positive DVT-arm were ≤ 30 years of age. When comparing HIV-positive 
and negative patients with thrombosis, the HIV-negative group was 
significantly older than the HIV-positive group.(41.45 vs. 32 years). The mean 
age of our HIV-positive patients with thrombosis was even lower than that of 
Saber [31] (43 years) and Saif [30] (39 years). The incidence of thrombosis 
strongly depends on age. It is a very rare disorder in the young and a common 
affliction in the elderly. Venous thrombosis is a multicausal disease; more than 
one risk factor needs to be present before thrombosis occurs. Thrombosis 




The younger an individual, the more risk factors are needed to precipitate 
thrombosis.[38] In children, 3 or 4 risk factors are required before thrombosis 
occurs, whereas in individuals aged 55 years and older, thrombosis will 
almost invariably occur when two or more risk factors are present. The 
number of risk factors needed to cause thrombosis decreases with age, which 
itself appears as a risk factor for thrombosis.[38] DVT is uncommon in young 
patients unless predisposing factors such as malignancy and congenital 
thrombophilia are present.[38] HIV-positive patients with thrombosis in our 
study did not have any of the recognised risk factors for thrombosis, i.e., 
malignancy, hereditary thrombophilia and recent surgery. Considering that no 
other predisposing factors were identified, HIV infection and its complications 
are a strong consideration as risk factors for thrombosis. This postulate is 
reinforced by the retrospective study by Copur et al. in which the frequency of 
VTE was significantly higher in HIV-positive patients under 50 years 
compared to HIV-negative patients under 50 years (3.315 vs. 0.53%; p < 
0.0001).[20] Also, the rate of VTE was significantly greater in the older HIV-
negative patients compared to the younger HIV-negative patients (p < 
0.0001). Among HIV-positive patients under 50 with VTE, risk factors for VTE 
were present in 3 of 10 patients (30%) as compared to 21 of 35 patients 
(60%) in the HIV-negative group under 50 years. 
 
There is uncertainty regarding the importance of the stage of HIV infection in 
the predisposition to thrombosis. Some studies have suggested that patients 
with clinical or immunological AIDS were more predisposed to deep vein 




significant increased risk for patients with a CD4 count < 200 cells/mm3 
compared to those with a CD4 count  > 200 cells/mm3.[3,29] 
 
The mean CD4 count in our study was lower in the HIV-positive DVT-arm 
when compared to the control-arm but the difference was not statistically 
significant (p = 0.461). Seventeen (17) of the 30 patients (57%) tested in the 
DVT-arm had CD4 counts <200 cells/mm3. The findings in this study are 
limited as only 30 patients in the DVT-arm had their CD4 counts done and 
clinical HIV staging was not done. The lack of data regarding the clinical stage 
of HIV infection and the small number of patients tested makes analysis 
difficult and may have precluded us from showing the impact of AIDS on the 
occurrence of DVT. 
 
Although tuberculosis was not one of the primary determinants of this study, a 
history of active tuberculosis on treatment was an independent risk factor for 
DVT in the HIV-positive group as determined by multivariate analysis. The risk 
of DVT was increased 2.9-fold for patients with tuberculosis. Significantly, 
31.8% of patients in the HIV-negative cohort with thrombosis had a history of 
tuberculosis on treatment. Six (6) of the patients in the HIV-positive DVT-arm 
and seven patients in the HIV-negative thrombosis group had bilateral 
thromboses. Analysis of these patients revealed tuberculosis as a possible 
risk factor. Four of the 13 patients (2 in the HIV-positive group and 2 in the 
HIV-negative group) had a history of tuberculosis on treatment and a further 3 




this is unclear, as these patients were not fully investigated  for abdominal 
pathology. 
The global burden of tuberculosis was estimated at 9 million cases in 2004. It 
is estimated that 80% of tuberculosis occurs in sub-Saharan Africa and Asia.  
Sub-Saharan Africa is one of the areas with the highest burden of both TB 
and HIV infection. South Africa has the largest number of people living with 
HIV infection in the world and ranks ninth on a list of twenty-two high burden 
TB countries (i.e., incidence rate of 558 per 100 000).[40]   Worldwide, 
tuberculosis is one of the common opportunistic diseases in those infected 
with HIV.[40] People at risk for HIV infection are also at risk for tuberculous 
infection. Numerous reports and epidemiological studies have confirmed the 
association between HIV and tuberculosis.[39] HIV infection impairs cellular 
immunity, the latter being responsible for containing latent tuberculosis and 
new exposure to Mycobacterium.[41] The link between tuberculosis and DVT in 
this study suggests that tuberculosis may be an important  predisposing factor 
in the pathogenesis of DVT both in the HIV-positive and negative patients  in 
an area where tuberculosis and HIV  are endemic. 
The association between tuberculosis and deep vein thrombosis has 
previously been reported. However, this finding has never been validated in 
the HIV-infected population. Deep vein thrombosis is clinically observed and 
can be confirmed with laboratory methods in 3 to 4 % of patients with 
pulmonary tuberculosis (PTB). The real incidence may, however, be closer to 
10% because it is thought to be clinically unclear in most patients.[42] 
There are several postulates on why patients with tuberculosis are 




characterised by an acute phase response and a hypercoagulable state.[42] 
Experimental studies have shown that peripheral blood mononuclear cells in 
PTB can be readily induced to produce interleukin-1 (IL-1), IL-6 and tumour 
necrosis factor-alpha (TNF-α). It is likely that the vascular endothelium could 
be primed as a result of the interaction between mycobacterial products and 
the host monocyte-macrophage system, which then synthesises large 
amounts of TNF-α and IL-6. These cytokines induce hepatic acute phase 
responses that alter levels of coagulation factor proteins such as fibrinogen 
and factor VIII. It has been shown that the risk of DVT is four times higher in 
patients with fibrinogen levels over 5g/L.[42] Turken et al. looked for possible 
haemostatic disturbances that predisposed to venous thrombosis in patients 
with PTB.[42] They found that patients with PTB had decreased antithrombin, 
decreased protein C, increased fibrinogen and increased platelet aggregation, 
and that these levels improved with treatment of the PTB. Also, plasminogen 
activator inhibitor-1 levels were high and remained high even after treatment 
of PTB was commenced. Similarly, Robson et al. have found that elevated 
plasma fibrinogen with impaired fibrinolysis together with a decrease in 
antithrombin and a thrombocytosis would favour the development of DVT in 
patients with PTB.[43] Deep vein thrombosis can occur due to venous 
obstruction caused by retroperitoneal lymphomas and malignant masses. In 
HIV-infected patients, tuberculosis is frequently extrapulmonary and 
disseminated. Sites commonly affected in extrapulmonary tuberculosis are 
lymph nodes, intestine, peritoneum, genitourinary tract and bones.[39] 
Tubercular lymph nodes may cause inferior vena cava obstruction and 




another procoagulant factor in patients with PTB.[44] Rifampicin is associated 
with proliferation of smooth endoplasmic reticulum of the hepatocyte and with 
the induction of cytochrome p450. This could alter the balance of 
anticoagulant and procoagulant proteins produced by the liver.[44] Therefore, 
PTB leads to alteration in haemostasis which, together with immobility 
associated with hospitalisation and anti-tuberculous therapy, predisposes to 
DVT.  The diagnosis of tuberculosis in this study was ascertained by the 
patient’s history of current therapy for tuberculosis and was not confirmed by 
microbiological or tissue diagnosis. Considering that the diagnosis of TB was 
not the primary aim of the study, there are shortfalls that need to be 
addressed in further studies. Reliance was placed on the patient’s clinical 
history for the documentation of tuberculosis. In further studies details of 
diagnosis of tuberculosis will need to be ascertained. Also, the site and 
possible dissemination of TB will need to be assessed. Careful assessment of 
treatment in patients already on anti-tuberculosis therapy will be required in 
view of the possible thrombogenic role of rifampicin.[44] The recognition of 
tuberculosis as a risk factor could make a case for prophylaxis against deep 
vein thrombosis in this population. Further studies are indicated both in HIV- 
positive and negative patients with tuberculosis to investigate accurately the 
real risk for the development of DVT as well as the possible pathogenesis of 
DVT in these patients . 
 
The mean globulin levels were increased both in the HIV-positive DVT-arm 
and the control-arm and there was no statistically significant difference 




negative patients with DVT, globulin levels were significantly increased in the 
HIV-positive cohort. 
 
The mean haemoglobin as well as  albumin levels were significantly reduced 
in the HIV-positive DVT-arm (p = 0.024 and < 0.001 respectively). This might 
signify more advanced HIV infection in this cohort. More investigations are 
needed to identify the possible mechanisms. 
 
 Mean fibrinogen levels were within normal limits in both HIV-positive groups 
and no significant difference was noted on univariate analysis. However, when 
comparing HIV-positive and negative patients with thrombosis, mean 
fibrinogen levels were elevated and significantly higher in the HIV-negative 
group of patients (p = 0.05). 
 
ANF, ACA and lupus anticoagulant were not found to be significant risk 
factors predisposing to DVT in this study. Eighteen (18) patients in the HIV- 
positive DVT group and 20 patients in the control group had positive ACA 
screens. There have been several reports [49,50,51] commenting on the  
significance of a positive ACA screen in HIV-positive patients. Elevated 
anticardiolipin antibodies are found in 20-70% of HIV-positive patients. 
However, despite the high prevalence of ACA and lupus anticoagulant, the 
clinical manifestations of classic antiphospholipid antibody syndrome are 
distinctly unusual.[51] It is postulated that APL antibodies encountered in HIV 
infection do not share the features of immune APL antibodies and that they 




alloimmune rather than autoimmune antibodies are found, and these have not 
been associated with thromboembolic events.[49] 
 
Mean protein C levels were significantly reduced in the HIV-positive DVT-arm 
compared to the HIV-positive controls (p = 0.016) as well as when compared 
to the HIV-negative patients with thrombosis (p =0.02).  Interpretation of the 
low protein C level is complicated by the fact that levels can be reduced in 
acute thrombosis [4] as well as in patients with PTB.[42] In our study, 52% of 
patients in the DVT-arm who had TB and 66% of patients in the control-arm 
who had TB, had decreased protein C levels. We were unable to repeat these 
tests after the acute thrombotic phase as these patients were lost to follow up. 
 
Mean total protein S levels were higher in the HIV-positive DVT-arm 
compared to the control-arm (81.15 vs. 69.29). However, they were both 
within the normal range. When comparing HIV-positive and negative patients 
with thrombosis, total protein S levels were significantly lower in the HIV- 
positive cohort.  Although previous studies [33,45] suggested that protein S was 
a risk factor for thrombosis in HIV-positive patients, no significant association 
between protein S and thrombosis was observed in this study. Results could, 
however, have been affected by missing data. In this study, protein S levels 
were assayed in only 41 of the HIV-positive patients with DVT. Another 
possible limitation was that we did not measure free protein S levels as only 
total protein S assays were available at the time in our laboratory. Free protein 
S levels are more reliable than total protein S. However, studies have shown a 




The mean activated protein C resistance (APCR) values were normal in the 
HIV-positive thrombosis group as well as the control group. All 26 patients 
analysed in the DVT-arm had normal APCR levels. Factor V Leiden is the 
primary cause of activated protein C resistance.[15] This finding correlates with 
other studies which have shown that the prevalence of factor V Leiden is 
highest amongst people of European origin and is very rarely found amongst 
Blacks.[46,47,48] 
 
Mean antithrombin levels were normal in the HIV-positive DVT-arm, the 
control-arm as well as the HIV-negative group with thrombosis. 
 
Many studies [22,23,24,25]  , including ours have found decreased levels of protein 
C, S or antithrombin, both in HIV-positive patients with DVT and those without 
DVT. Bissuel et al. evaluated 63 HIV-positive patients and of these, 41 had 
low free protein S levels.[23] Yet only three of these patients had a thrombotic 
event. All three patients had full-blown AIDS and had active infections. Stahl 
found 19 patients with reduced free protein S levels and only three of them 
had thrombosis.[24] Some of the studies showed low protein S levels in 
patients with HIV, yet none of the patients had thrombosis.[22,28] Feffer et al. 
found decreased protein C and free protein S in patients with HIV, yet none of 
them had thrombosis.[28] These findings suggest that reduced levels of protein 
C, S and antithrombin do occur in HIV-positive patients, but that this alone is 
not enough to result in thrombosis. Venous thrombosis is a multicausal 
disease; more than one risk factor needs to be present before thrombosis 




present simultaneously. It suggests that a combination of factors, which 
include infections, malignancy and immobilisation, together with reduced 
anticoagulant factors, result in the development of thrombosis. It is possible 
that different combinations of factors are responsible in each patient. 
 
There were limitations in this study which will need to be addressed in future 
studies. The original intention of this study was to have enrolled an additional 
arm of HIV-negative subjects with proven DVT to interrogate possible specific 
associations with HIV infection. However, only 22 HIV-negative patients with 
DVT that met our inclusion criteria presented to the hospital during this period.  
We were only able to extract limited data for this group, as some of the data 
was unavailable. 
 
As alluded to earlier, owing to logistical problems, many patients in the study 
did not have CD4 counts and protein C and S levels done. 
 
We performed total protein S levels in the study. Both free and total protein S 
levels may be more informative in future studies. 
 
Ideally, coagulation testing should have been done after the acute thrombotic 
phase. We were unable to repeat these tests at a later time because of poor 
follow-up. 
 
We also did not ascertain from patients whether they had been immobilised 




Tuberculosis has emerged as an important risk factor for DVT in this study. As 
alluded to earlier, in future studies there will have to be careful screening for 
tuberculosis in patients with DVT. 
 
We did not assess our patients for other infections associated with immune 
deficiency. Many of these infections are considered an additional risk factor 
for thrombosis. Squizzato, Gerdes et al. [53]  reviewed published human 
studies on the influence of cytomegalovirus (CMV) infection on the 
coagulation system. They found that it was likely that CMV is involved in the 
pathogenesis of thrombosis but that further studies were required to evaluate 
the role of CMV as a risk factor for thrombosis. In vitro experiments have also 
suggested that other viruses such as Herpes simplex virus type 1 and 2, 
respiratory syncytial virus and adenovirus, might have procoagulant effects as 
well.[52]  Also, although none of our patients at the time of assessment gave a 
history of malignancy, we did not definitively exclude malignancy  as a 
predisposing factor for thrombosis. 
 
Although none of patients were on antiretroviral therapy, this is an additional 
factor that will have to be taken into consideration in future studies. George et 
al. found that the incidence of venous thrombotic events increased 
dramatically from 0.19% before the introduction of protease inhibitors to 
1.07% afterwards.[53] However, recently Fultz et al. reported finding no 
significant increase.[54] Thus, it is not yet clear whether antiretroviral therapy is 
associated with an increased risk of DVT. The postulated mechanisms could 




and lipid. Further studies would be required to establish whether HAART adds 
to the risk of DVT.[33] 
 
This study highlights the importance of HIV and tuberculosis as possible risk 
factors for the development of DVT. In a population such as ours in Sub-
Saharan Africa , where  the prevalence of both tuberculosis and HIV is high, 
confirmation of our findings will have important implications in terms of 
prophylaxis against DVT in vulnerable populations. Further studies are 
therefore required to address the  limitations of our study and add to the 





















HIV-positive and negative African (Black) patients with deep vein thrombosis  
as well as HIV-positive patients without DVT were analysed to identify 
possible coagulation factor abnormalities predisposing to the development of 
deep vein thrombosis in  HIV-positive  patients. 
 
A compelling argument for HIV being a significant predisposing factor in the 
pathogenesis of DVT is that 50 of the 77 randomly referred patients with DVT 
were HIV-positive and that the HIV-positive group were young patients with no 
other recognised risk factor for the development of DVT. The mean age of the 
HIV-positive patients with DVT was 32 years. The HIV-negative group with 
DVT were significantly older than the HIV-positive group (42 vs. 32 years). 
The mean CD4 count in the HIV-positive patients with thrombosis was 202 
cells/mm3.  A low CD4 count was not found to be a significant predisposing 
factor for thrombosis. 
 
Mean protein C levels were significantly reduced in the HIV-positive DVT-arm 
compared to the HIV-positive group without thrombosis. Protein C levels were 
significantly reduced on bivariate, but not on multivariate analysis. When 
comparing the HIV-positive and HIV-negative patients with thrombosis, mean 
protein C levels were significantly reduced in the HIV-positive patients. Mean 
protein S levels were normal in both DVT-arms as well as the control-arm. 
However, the mean protein S levels was significantly lower in the HIV-positive 




Mean antithrombin levels were normal in the HIV-positive and negative  DVT 
groups as well as in the  control-arm and there was no statistically significant 
difference between the groups. 
 
A positive D-dimer was significant both on bivariate and multivariate analysis 
in HIV-positive patients with thrombosis compared to the HIV-positive control 
group. 
 
Although not a primary aim of the study, tuberculosis was a significant factor 
predisposing to the development of DVT in the HIV-positive patients both on 
univariate and multivariate analysis. Twenty-two (22) of the 50 HIV positive 
patients (44%) with DVT gave a history of being treated for tuberculosis. Also 
important is that 7 of the 22 patients (31.8%) analysed in the HIV-negative 
group with thrombosis had a history of tuberculosis on treatment. With both 
HIV and tuberculosis being endemic in our population, tuberculosis might be 
an important risk factor predisposing to DVT both in the HIV-positive and 
negative patients. Further studies are needed to confirm this finding as, in this 
study, the diagnosis of tuberculosis was made only from the history obtained 
from the patient. 
 
Patients with classic thrombophilic risk factors such as malignancy and recent 
surgery were excluded from the study. It is well known that HIV-positive 
patients have an increased incidence of malignancy. This would further 





The findings of his study add credence to postulates by other authors that the 
pathogenesis of thrombosis in HIV-infected patients is multifactorial. Venous 
thrombosis is a multicausal disease; more than one risk factor needs to be 
present before thrombosis occurs. Thrombosis occurs when a sufficient 
number of risk factors are present simultaneously. It suggests that a 
combination of factors, which include infections, malignancy and 
immobilisation, together with reduced anticoagulant factors, result in the 
development of thrombosis. It is possible that different combinations of factors 
are responsible in each patient.  There are several intersecting mechanisms 
associated with HIV and its complications that may predispose these patients 
to thrombosis. HIV may contribute to thrombosis by direct as well as indirect 
means. HIV infection could cause hypercoagulability by affecting endothelial 
function, causing perturbation of fibrinolysis as well as by causing reduction of 
levels of protein C, S and antithrombin. Opportunistic infections such as 
tuberculosis as well as cytomegalovirus could also predispose to thrombosis. 
Patients with HIV infection are also predisposed to the development of cancer  
which further predisposes patients to thrombosis. Additionally, there are 
suggestions that  antiretroviral therapy, especially protease inhibitors, could 
predispose to thrombosis. 
 
The lack of consensus regarding the pathogenesis of thrombosis in HIV- 
positive patients could partly be explained by the variability and multiplicity of 
predisposing factors depending on the stage of infection, associated 
infections, malignancy as well as drug history. This study highlights the 




DVT. Further studies are indicated to confirm these postulates so that 
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(b) CONSENT FORM: ENGLISH 
 
 
You have deep vein thrombosis. You will have blood tests done on you. 
These blood tests are performed on all patients with this condition. The 
reason we require your consent is that we shall be using the results for a 
study on this condition. You will be treated in the same way as all patients with 
deep vein thrombosis. However, in your case we shall do an additional test for 
human immunodeficiency virus as we want to establish if there is any relation 
between this disease and immunodeficiency virus infection. 
 
You have a right to refuse performance of this test. If you agree to the 
performance of the tests you have the right to choose whether or not you wish 
to be informed of the results. 
 
All results will be treated in confidence. 
 
You also have the right to withdraw from the study at any time. If you refuse to 





(c) CONSENT FORM: ISIZULU 
 
Unesifo esidala ukuba libe yihlule phakathi emithanjeni yakho. Kukhona 
amagazi okuzodinga sizodinga siwathathe ukuze sense ama test athile. Lama 
“test” ayenziwa kubo bonke abantu abanaiesisfo, Indlela ozolashwa nhayo 
ngeke yehlike kuleyo abanye anbtu abelashwa ngayo. Kuzodingeka futhi 
sithathe igazi ukuze siyohola igciwane lengculazi, lokhu sikwenzela ukubu 
kesibheke ukuthi lesisifo asihambelani yini naleligciwane. 
 
Unegunya lokwala ukwenziwa kwalama “test”. Uma kwenzeka uvuma sense 
lama “test” uwena oyosho noma uyathanda yini ukuyazi imiphumela yawo. 
Uma ufuna siyokutshela, uma ungafuni ngeke siklutshele, Lolulwazi 
esizolwazi ngawe loyokwaziwa yithi kuphela, amukho amunye omunye 
omunty oyoke azi. Kuyilungelo lakho ukuba usho noma yinini ukuthi ufuna 
ukuyeka ukuba sisebenzise imiphumela yakho kuloluphenyo. 
 
Noma ungafuni ukuba kuloluhlelo lokufunda ngalesisifo, lokho akusho ukuthi 









(d) .NORMAL RANGES 
• Haemoglobin (Hb)                       11.5  -13.5 g/dl     (females) 
                                                                            13.5- 15.5 g/dl     (males) 
• White cell count                          4 – 11 x 109 /L 
• Platelets                                       150- 450 x 109 /L 
• International normalised ratio (INR)          < 1.2 
• Partial Thromboplastin Time (PTT)          29-45 sec 
• Fibrinogen                                     1.5-4.5 g/L 
• D-dimer 
o negative                              < 500ng/ml 
• Antinuclear factor                          negative 
• Anticardiolipin antibody                  negative 
 
• Lupus anticoagulant                      < 45 sec 
• Protein   C                                      70 – 140 % 
• Protein  S                                       60 – 140 % 
• Antithrombin                                80 – 120  % 
• APC  resistance                                    2 - 5 
• CD4  count                                               550 –1955 cells/mm3 
• Globulin                                                    20 – 32 g/L 
• Albumin                                                    32 – 50 g/L 
• Urea                                                          2.5 – 6.6 mmol/L 
• Creatinine                                                  53 –115 umol /L 
